Thirty Madison, a D2C telehealth unicorn, has entered into a definitive agreement to merge with a specialty care platform Nurx in an all-stock deal. The company plans to widen its portfolio of products and services under the Thirty Madison brand via the acquisition. The financial terms of the transaction are yet to be disclosed and are subject to regulatory approval. The deal is expected to close in 1H2022.

The integrated platform will cater to nearly 750,000 patients, offering a range of specialty care services from birth control to chronic disease management. The combined company plans to grow its B2B operations via partnerships with national payers and employers. It expects revenue to reach USD 300 million in 2022.

The announcement follows Thirty Madison raising USD 140 million in Series C funding at a USD 1 billion valuation in June 2021.

California-based Nurx provides virtual specialty care across a wide spectrum of health conditions including sexual health, migraine care, and dermatology. It partners with health plans such as Aetna and Anthem to offer a B2B2C service. Nurx was valued at USD 332 million prior to the merger.